PMID- 35623464
OWN - NLM
STAT- MEDLINE
DCOM- 20220812
LR  - 20221018
IS  - 1532-8392 (Electronic)
IS  - 0046-8177 (Linking)
VI  - 126
DP  - 2022 Aug
TI  - Digital imaging correlation of immunohistochemistry and fluorescence in situ 
      hybridization in breast carcinoma cases with HER2 genetic heterogeneity.
PG  - 129-135
LID - S0046-8177(22)00137-X [pii]
LID - 10.1016/j.humpath.2022.05.011 [doi]
AB  - Genetic heterogeneity (GH) is a rare but important event in the evaluation of 
      HER2 amplification status. We investigated whether HER2 fluorescence in situ 
      hybridization (FISH) GH correlated with increased protein expression by 
      immunohistochemistry (IHC) and/or morphologic features using image analyses. 
      Retrospective search of HER2 FISH GH cases 2016-2020 was performed. Cases with 
      both FISH and IHC slides available were considered eligible and were digitally 
      imaged. Additional demographic, histological, and treatment information was 
      compiled from pathology and medical records when available. Overall, 11 of 
      15 cases (73.3%) had HER2 FISH GH that matched to areas of HER2 overexpression or 
      focally different morphology. Nine cases with areas of gene amplification 
      overlapped with <10% of intense circumferential protein expression ("Mini 3+"), 
      and 1 case with focal micropapillary features. Clinical information was available 
      on 6 patients (40%), all were alive with no evidence of disease (mean follow-up 
      30.5 months; range, 12-65 months). One patient with GH and a lymph node 
      metastasis showed nonamplified population in the nodal tumor. GH, when defined as 
      discrete clusters of amplified cells following 2013 ASCO/CAP guidelines, even 
      when less than 10% of the tumor cells, frequently has morphologic correlates such 
      as focal intense protein overexpression or micropapillary morphology. Clinical 
      significance of these focal gene amplification and protein overexpression needs 
      to be further investigated.
CI  - Copyright (c) 2022. Published by Elsevier Inc.
FAU - Wilcock, Diane M
AU  - Wilcock DM
AD  - ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108, USA.
FAU - Sirohi, Deepika
AU  - Sirohi D
AD  - ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108, USA; University of 
      Utah, Department of Pathology, Huntsman Cancer Institute, 2000 Circle of Hope, 
      Room 3100, Salt Lake City, UT 84124, USA.
FAU - Coleman, Joshua F
AU  - Coleman JF
AD  - ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108, USA; University of 
      Utah, Department of Pathology, Huntsman Cancer Institute, 2000 Circle of Hope, 
      Room 3100, Salt Lake City, UT 84124, USA.
FAU - Gulbahce, H Evin
AU  - Gulbahce HE
AD  - ARUP Laboratories, 500 Chipeta Way, Salt Lake City, UT 84108, USA; University of 
      Utah, Department of Pathology, Huntsman Cancer Institute, 2000 Circle of Hope, 
      Room 3100, Salt Lake City, UT 84124, USA. Electronic address: 
      Evin.Gulbahce@path.utah.edu.
LA  - eng
PT  - Journal Article
DEP - 20220524
PL  - United States
TA  - Hum Pathol
JT  - Human pathology
JID - 9421547
RN  - EC 2.7.10.1 (Receptor, ErbB-2)
SB  - IM
MH  - *Breast Neoplasms/pathology
MH  - Female
MH  - Gene Amplification
MH  - Genetic Heterogeneity
MH  - Humans
MH  - Immunohistochemistry
MH  - In Situ Hybridization, Fluorescence/methods
MH  - *Receptor, ErbB-2/analysis
MH  - Retrospective Studies
OTO - NOTNLM
OT  - Digital image
OT  - FISH
OT  - Genetic heterogeneity
OT  - HER2
OT  - Micropapillary
EDAT- 2022/05/28 06:00
MHDA- 2022/08/13 06:00
CRDT- 2022/05/27 19:24
PHST- 2022/05/05 00:00 [received]
PHST- 2022/05/18 00:00 [accepted]
PHST- 2022/05/28 06:00 [pubmed]
PHST- 2022/08/13 06:00 [medline]
PHST- 2022/05/27 19:24 [entrez]
AID - S0046-8177(22)00137-X [pii]
AID - 10.1016/j.humpath.2022.05.011 [doi]
PST - ppublish
SO  - Hum Pathol. 2022 Aug;126:129-135. doi: 10.1016/j.humpath.2022.05.011. Epub 2022 
      May 24.